A phase III randomized, open-label study of CG1940 and CG8711 [cancer vaccine-GVAX] versus docetaxel [Taxotere] and prednisone in patients with metastatic hormone-refractory prostate cancer who are chemotherapy-naive

Trial Profile

A phase III randomized, open-label study of CG1940 and CG8711 [cancer vaccine-GVAX] versus docetaxel [Taxotere] and prednisone in patients with metastatic hormone-refractory prostate cancer who are chemotherapy-naive

Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Sep 2016

At a glance

  • Drugs Docetaxel (Primary) ; Prednisone (Primary) ; Tumour cell vaccine-GVAX (Primary)
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms VITAL-1
  • Most Recent Events

    • 28 Feb 2009 Final results were presented at the ASCO 2009 Genitourinary Cancers Symposium.
    • 17 Oct 2008 Status changed from active, no longer recruiting to discontinued (Independent Data Monitoring Committee showed that the trial had less than 30% chance of meeting its primary endpoint).
    • 29 Sep 2008 Checked against clinicltrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top